It’s only fair to share… Claziprotamide CAS 2361124-03-8, BBP 671 MF C19H20ClFN4O MW374.8 g/mol 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-onepantothenate kinases 1 and 3 (PanK1 and PanK3) positive allosteric modulator Claziprotamide is an investigational new drug that is being evaluated for the treatment of rare metabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA). It acts as a positive allosteric modulator …
Camibirstat
It’s only fair to share… Camibirstat CAS 2671128-05-3 N-{(2S)-1-[(4-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl}-1,3-thiazol-2-yl)amino]-3-methoxy-1-oxopropan-2-yl}-1-(methanesulfonyl)-1H-pyrrole-3-carboxamideATPase inhibitor, antineoplastic MW C24H30N6O6S2 MF 562.7 g/mol Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.[1] It is being developed by Foghorn Therapeutics.[2] Camibirstat …
Brimarafenib
It’s only fair to share… Brimarafenib CAS 1643326-82-2 MF C24H17F3N4O4 MW482.4 g/mol N-{(1S,1aS,6bS)-5-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl}-N′-(2,4,5-trifluorophenyl)urearapidly accelerated fibrosarcoma (Raf) kinase inhibitor, Antineoplastic, MapKure, LLC, SpringWorks Therapeutics, BeiGene, BGB-3245, BGB 3245, GXS33OY2CB Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.[1][2] …
Brezivaptan
It’s only fair to share… Brezivaptan CAS 1370444-22-6 ANC-501, THY-1773, TS-121, 575OB1CKN0 MF C25H30ClN5O3 MW 484.0 g/mol 2-[3-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamidevasopressin receptor antagonist Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5] ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment …
Atumelnant
It’s only fair to share… Atumelnant CAS 2392970-97-5 MF C33H42F3N5O3 MW 613.7 g/mol CRN04894, NR57FH6U1N CRINETICS PHARMA, Orphan Drug Status, Congenital adrenal hyperplasia N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-[(2R)-2-ethyl-4-[1-(trifluoromethyl)cyclobutanecarbonyl]piperazin-1-yl]pyridine-2-carboxamide N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-6-(2-ethoxyphenyl)-3-{(2R)-2-ethyl-4-[1-(trifluoromethyl) cyclobutane-1-carbonyl]piperazin-1-yl}pyridine-2-carboxamideAdrenocorticotropic hormone receptor antagonist Atumelnant (INNTooltip International Nonproprietary Name; developmental code name CRN04894) is an investigational new drug developed by Crinetics Pharmaceuticals for the treatment of adrenocorticotropic hormone (ACTH)-dependent endocrine disorders.[1] It is a selective antagonist of the melanocortin type 2 receptor (MC2R), also …
Ateganosine
It’s only fair to share… Ateganosine CAS 789-61-7 MF C10H13N5O3S MW 283.31 g/mol 2′-deoxy-6-thioguanosinenucleoside analogue, antineoplastic Ateganosine is a telomerase inhibitor[1] and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).[2] Beta-Thioguanine Deoxyriboside is a thiopurine nucleoside derivative with antineoplastic activity. After conversion to the triphosphate, beta-thioguanine deoxyriboside is incorporated into DNA, resulting in inhibition of DNA replication. This …
Bimokalner
It’s only fair to share… Bimokalner CAS 2243284-19-5 MF C15H18F5NOS MW 355.4 g/mol (1S,2S,4R)-N-{[3-(pentafluoro-λ6sulfanyl)phenyl]methyl} bicyclo[2.2.1]heptane-2-carboxamidevoltage-gated potassium channel (Kv7.4) agonist Bimokalner is an investigational new drug under evaluation for preventing and treating hearing loss caused by cisplatin treatment. It is a voltage-gated potassium channel agonist targeting Kv7.4 and is being developed by Acousia Therapeutics GmbH.[1][2] PAT Compounds useful as potassium channel openers, Publication Number: US-11884642-B2, Priority Date: 2017-02-28, Grant Date: 2024-01-30 …
Asengeprast
It’s only fair to share… Asengeprast CAS 1001288-58-9 FT011, FT 011, orphan drug status, systemic sclerosis, SHP-627, SHP 627, Fast Track 2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid 2-[(2E)-3-{3-methoxy-4-[(prop-2-yn-1-yl)oxy]phenyl}prop-2-enamido]benzoic acid G protein-coupled receptor 68 (GPR68) antagonist,anti-inflammatory MF C20H17NO5 MW 351.4 g/mol. C6V7ZU2NPR Asengeprast (development code FT011) is an experimental scleroderma drug candidate.[1] It is a small molecule inhibitor of the G-protein coupled receptor GPR68 with antifibrotic activity.[2] It is …
Asandeutertinib
It’s only fair to share… Asandeutertinib, Osimertinib-d3 CAS 1638281-46-5 N-[2-{2-(dimethylamino)ethylamino}-4-methoxy-5-({4-[1-(2H3)methyl-1H-indol-3-yl]pyrimidin-2-yl}amino)phenyl]prop-2-enamideepidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, antineoplastic MF C28H30. 2H3. N7O2, C28H30D3N7O2 MW 502.6 g/mol Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties.[1][2] Developed by TYK Medicines, this small molecule drug is currently …
Admilparant
It’s only fair to share… Admilparant, (BMS-986278) CAS 2170126-74-4 MF C22H31N5O5 MW 445.5 g/mol (1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-l]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acidlysophosphatidic acid receptor 1 (LPA1) antagonist Admilparant is an investigational new drug being developed by Bristol-Myers Squibb for the treatment of idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). It is a first-in-class lysophosphatidic acid receptor 1 (LPA1) antagonist.[1][2] As of 2024, admilparant is in Phase III clinical trials …